Inovio Pharmaceuticals Inc (NASDAQ:INO) saw its shares tumble 37.1% on Thursday after disclosing an underwritten, dilutive public offering of common stock and related warrants.
The company said it priced an offering of 12,500,000 shares of common stock together with accompanying warrants at a price of $1.40 per share. The package contains both Series A and Series B warrants, each providing the right to acquire up to 12,500,000 additional shares at an exercise price of $1.40 per share.
The filing states the transaction is expected to close on or about April 6, 2026, subject to customary closing conditions. As part of the arrangement, Inovio has granted the underwriter a 30-day option to purchase up to 1,875,000 more shares along with corresponding warrants.
Assuming the accompanying warrants are not exercised, the company anticipates gross proceeds of approximately $17.5 million from the offering before subtracting underwriting discounts, commissions, and offering-related expenses. Piper Sandler is identified as the sole manager for the offering.
Market reaction to the announcement was immediate: the company's stock fell sharply on the day of the disclosure. The filing and terms of the offering were the proximate cause cited for the sell-off in the security.
Inovio's stated focus remains on developing DNA-based medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases. The company description in the offering paperwork reiterates these therapeutic areas as the core of its research and development efforts.
Summary of offering terms
- 12,500,000 shares of common stock priced at $1.40 per share.
- Series A and Series B warrants to purchase up to 12,500,000 shares each at $1.40 per share.
- Underwriter 30-day option for up to 1,875,000 additional shares and accompanying warrants.
- Expected close on or about April 6, 2026, subject to customary conditions.
- Estimated gross proceeds of approximately $17.5 million before underwriting discounts, commissions, and offering expenses, assuming no warrant exercises.
- Piper Sandler acting as sole manager.
This disclosure of financing plans and the exact mechanics of the securities offered - including the presence of sizeable warrants and an additional underwriter option - formed the basis of the market move on Thursday.